EORTC

EORTC – Understanding long-term quality of life after completion of an adjuvant treatment for melanoma

EORTC – European Organisation for Research and Treatment of Cancer shared on LinkedIn:

” Have you read our latest publication in The Lancet Oncology?

Understanding patients’ health-related quality of life after completion of an adjuvant treatment for melanoma is important.

The research area concerns patients who are likely to become cancer survivors and would be impacted by potential long-term adverse effects. This publication provides results on the long-term health-related quality of life of melanoma patients treated with a PD-1 inhibitor. ”

‘Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial‘

Authors: Emanuel Bührer, Michal Kicinski, Mario Mandala, Madeline Pe, Prof Georgina V Long, Victoria Atkinson, Christian U Blank, Andrew Haydon, Prof Stéphane Dalle, Adnan Khattak, Matteo S Carlino, Prof Andrey Meshcheryakov, Prof Shahneen Sandhu, Prof Susana Puig, Prof Dirk Schadendorf, Rahima Jamal, Prof Piotr Rutkowski, Prof Alfonsus J M van den Eertwegh, Corneel Coens, Dmitri Grebennik, Clemens Krepler, Prof Caroline Robert, Prof Alexander M M Eggermont.
EORTC - Understanding long-term quality of life after completion of an adjuvant treatment for melanoma

Source: EORTC/LinkedIn

Adnan Khattak Andrew Haydon cancer Christian U. Blank Clemens Krepler Corneel Coens Dmitri Grebennik Emanuel Bührer EORTC Madeline Pe Mario Mandala Matteo S Carlino Melanoma Michal Kicinski OncoDaily Oncology Prof Alexander M M Eggermont Prof Alfonsus J M van den Eertwegh Prof Andrey Meshcheryakov Prof Caroline Robert Prof Dirk Schadendorf Prof Georgina V Long Prof Piotr Rutkowski Prof Shahneen Sandhu Prof Stéphane Dalle Prof Susana Puig Rahima Jamal The Lancet Oncology Victoria Atkinson